Partial agonist activity of bucindolol is dependent on the activation state of the human β1-adrenergic receptor

Circulation

Volumn 108, Issue 3, 2003, Pages 348-353

  Maack, Christoph ^a   Böhm, Michael ^a   Vlaskin, Lydia ^b   Dabew, Ewtim ^a   Lorenz, Kristina ^b   Schäfers, Hans Joachim ^a   Lohse, Martin J ^b   Engelhardt, Stefan ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Genetics; Heart failure; Inotropic agents; Receptors, adrenergic, beta

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; FORSKOLIN; ISOPRENALINE; METOPROLOL; PARTIAL AGONIST; PROPRANOLOL; XAMOTEROL;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; ELECTROSTIMULATION; FEMALE; HEART BEAT; HEART FAILURE; HEART LEFT VENTRICLE MUSCLE; HEART MUSCLE CONTRACTILE FORCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INOTROPISM; ISOLATED HEART; MALE; MORTALITY; MOUSE; MUSCLE EXCITATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SPECIES DIFFERENCE; TISSUE CULTURE; TRANSGENIC MOUSE; WILD TYPE;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ATRIAL FUNCTION; HEART ATRIA; HEART FAILURE, CONGESTIVE; HEART RATE; HUMANS; MALE; METOPROLOL; MICE; MICE, TRANSGENIC; MIDDLE AGED; MYOCARDIAL CONTRACTION; ORGAN SPECIFICITY; PROPANOLAMINES; PROPRANOLOL; RECEPTORS, ADRENERGIC, BETA-1; SPECIES SPECIFICITY; XAMOTEROL;

EID: 0041306936     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000080325.94345.8B     Document Type: Article

References (24)

1. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation. 2000;101:558-569.
2. Nicholas G, Oakley C, Pouleur H, et al. Xamoterol in Severe Heart Failure Study Group: Xamoterol in severe heart failure. Lancet. 1990;336:1-6.
3. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659-1667.
4. Milligan G, Bond RA, Lee M. Inverse agonism: pharmacological curiosity or potential therapeutic strategy? Trends Pharmacol Sci. 1995;16:10-13.
5. 1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A. 1999;96:7059-7064.
6. 2-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation. 1999;100:2210-2212.
7. 1-adrenergic receptor in transgenic mice. J Mol Cell Cardiol. 2000;32:817-830.
8. Willette RN, Aiyar N, Yue TL, et al. In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats. J Pharmacol Exp Ther. 1999;289:48-53.
9. 1-receptor transgenic mice. Mol Pharmacol. 2001;60:712-7.
10. Böhm M, Mittmann C, Schwinger RH, et al. Effects of xamoterol on inotropic and lusitropic properties of the human myocardium and on adenylate cyclase activity. Am Heart J. 1990;120:1381-1392.
11. Deitchman D, Byrne JE, Snyder RW. Cardiovascular effects of bucindolol (MJ 13105) in conscious dogs. Arch Int Pharmacodyn Ther. 1980;247:76-88.
12. Hershberger RE, Wynn JR, Sundberg L, et al. Mechanism of action of bucindolol in human ventricular myocardium. J Cardiovasc Pharmacol. 1990;15:959-967.
13. Brixius K, Bundkirchen A, Bölck B, et al. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br J Pharmacol. 2001;133:1330-1338.
14. Maack C, Cremers B, Flesch M, et al. Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium. Br J Pharmacol. 2000;130:1131-1139.
15. Andreka P, Aiyar N, Olson LC, et al. Bucindolol displays intrinsic sympathomimetic activity in human myocardium. Circulation. 2002;105:2429-2434.
16. 2-adrenergic receptor. Mol Pharmacol. 1996;50:662-669.
17. s-protein interaction and inverse agonism of nebivolol in human myocardium. Br J Pharmacol. 2001;132:1817-1826.
18. Darfler FJ, Mahan LC, Koachman AM, et al. Stimulation of forskolin of intact S49 lymphoma cells involves the nucleotide regulatory protein of adenylate cyclase. J Biol Chem. 1982;257:11901-11907.
19. s-adenylate cyclase interactions. FASEB J. 1991;5:2300-2303.
20. Brodde OE, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev. 1999;51:651-690.
21. Benovic JL, Staniszewski C, Mayor F, Jr, et al. Beta-adrenergic receptor kinase: activity of partial agonists for stimulation of adenylate cyclase correlates with ability to promote receptor phosphorylation. J Biol Chem. 1988;263:3893-3897.
22. Hausdorff WP, Caron MG, Lefkowitz RJ. Turning off the signal: desensitization of beta-adrenergic receptor function. FASEB J. 1990;4:2881-2889.
23. 2-adrenergic receptor antagonist, decreases beta-adrenergic receptor density in cultured embryonic chick cardiac myocyte membranes. J Cardiovasc Pharmacol. 2001;37:678-691.
24. alpha(s). J Biol Chem. 1999;274:31014-31019.